These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

107 related articles for article (PubMed ID: 28810949)

  • 1. Analysis of Non-Pivotal Bioequivalence Studies Submitted in Abbreviated New Drug Submissions for Delayed-Release Drug Products.
    Kaur P; Jiang X; Stier E
    J Pharm Pharm Sci; 2017; 20(0):252-257. PubMed ID: 28810949
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Requirements for submission of bioequivalence data; final rule. Final rule.
    Food and Drug Administration, HHS
    Fed Regist; 2009 Jan; 74(11):2849-62. PubMed ID: 19385107
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Comparing generic and innovator drugs: a review of 12 years of bioequivalence data from the United States Food and Drug Administration.
    Davit BM; Nwakama PE; Buehler GJ; Conner DP; Haidar SH; Patel DT; Yang Y; Yu LX; Woodcock J
    Ann Pharmacother; 2009 Oct; 43(10):1583-97. PubMed ID: 19776300
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Common Deficiencies of in vitro Binding Bioequivalence (BE) Studies Submitted in Abbreviated New Drug Applications (ANDAs).
    Lu D; Vivian D; Ren P; Yang Y; Zhang H; Jiang X; Stier E
    AAPS J; 2018 Jan; 20(2):26. PubMed ID: 29327295
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Applications of In Vitro-In Vivo Correlations in Generic Drug Development: Case Studies.
    Kaur P; Jiang X; Duan J; Stier E
    AAPS J; 2015 Jul; 17(4):1035-9. PubMed ID: 25896303
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Bioavailability and Bioequivalence Aspects of Oral Modified-Release Drug Products.
    Wang R; Conner DP; Li BV
    AAPS J; 2017 Mar; 19(2):360-366. PubMed ID: 28004346
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Common deficiencies with bioequivalence submissions in abbreviated new drug applications assessed by FDA.
    Liu Q; Davit BM; Cherstniakova SA; Dandamudi S; Walters JF; Lee CH; Raines KW; Ren K; Williamson LN; Conner DP
    AAPS J; 2012 Mar; 14(1):19-22. PubMed ID: 22130775
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Common bioanalytical deficiencies with bioequivalence submissions in Abbreviated New Drug Applications.
    Williamson LN; Conner DP; Stier EM; Davit BM
    Bioanalysis; 2014 Feb; 6(4):441-5. PubMed ID: 24568348
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Common Filing Deficiencies in Abbreviated New Drug Applications Containing Clinical Endpoint Studies.
    Fermaglich LJ; Chen R; Kim CY; Chuh EE; Thomas T; Shetty D; Lee J; Young J; Fan Y
    Ther Innov Regul Sci; 2019 Jan; 53(1):81-85. PubMed ID: 29719976
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Factors that have an Impact on Abbreviated New Drug Application (ANDA) Submissions.
    Wittayanukorn S; Rosenberg M; Schick A; Hu M; Wang Z; Babiskin A; Lionberger R; Zhao L
    Ther Innov Regul Sci; 2020 Nov; 54(6):1372-1381. PubMed ID: 32495310
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Bioequivalence of oxycodone hydrochoride extended release tablets to marketed reference products OxyContin® in Canada and US.
    Gosai P; Ducharme MP; Godfrey AR; Freeman JC; Monif T; Kumar KS; Kumar S; Mudnaik R; Katikaneni P
    Int J Clin Pharmacol Ther; 2013 Nov; 51(11):895-907. PubMed ID: 23673291
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Bioequivalence of topical clotrimazole formulations: an improved tape stripping method.
    Parfitt NR; Skinner MF; Bon C; Kanfer I
    J Pharm Pharm Sci; 2011; 14(3):347-57. PubMed ID: 21906479
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Biowaiver: an alternative to in vivo pharmacokinetic bioequivalence studies.
    Mishra V; Gupta U; Jain NK
    Pharmazie; 2010 Mar; 65(3):155-61. PubMed ID: 20383933
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Bioequivalence. An updated reappraisal addressed to applications of interchangeable multi-source pharmaceutical products.
    Marzo A; Balant LP
    Arzneimittelforschung; 1995 Feb; 45(2):109-15. PubMed ID: 7710428
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Is it possible to achieve bio-equivalence between an oral solid immediate-release and an analogue enteric-coated formulation?
    Licht D; Cohen R; Spiegelstein O; Rabinovich-Guilatt L; Zholkovsky M; Gilbert A; Dressman JB; Safadi M
    J Pharm Pharmacol; 2016 Oct; 68(10):1278-89. PubMed ID: 27465906
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Quantitative assessment of the switchability of generic products.
    Karalis V; Bialer M; Macheras P
    Eur J Pharm Sci; 2013 Nov; 50(3-4):476-83. PubMed ID: 23981332
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Pharmacokinetics, efficacy and toxicity of different pegylated liposomal doxorubicin formulations in preclinical models: is a conventional bioequivalence approach sufficient to ensure therapeutic equivalence of pegylated liposomal doxorubicin products?
    Mamidi RN; Weng S; Stellar S; Wang C; Yu N; Huang T; Tonelli AP; Kelley MF; Angiuoli A; Fung MC
    Cancer Chemother Pharmacol; 2010 Nov; 66(6):1173-84. PubMed ID: 20661737
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Investigation on the need of multiple dose bioequivalence studies for prolonged-release generic products.
    García-Arieta A; Morales-Alcelay S; Herranz M; de la Torre-Alvarado JM; Blázquez-Pérez A; Suárez-Gea ML; Alvarez C
    Int J Pharm; 2012 Feb; 423(2):321-5. PubMed ID: 22120644
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A perspective for biowaivers of human bioequivalence studies on the basis of the combination of the ratio of AUC to the dose and the biopharmaceutics classification system.
    Sakuma S; Tachiki H; Uchiyama H; Fukui Y; Takeuchi N; Kumamoto K; Satoh T; Yamamoto Y; Ishii E; Sakai Y; Takeuchi S; Sugita M; Yamashita S
    Mol Pharm; 2011 Aug; 8(4):1113-9. PubMed ID: 21630662
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Regulatory considerations of pharmaceutical solid polymorphism in Abbreviated New Drug Applications (ANDAs).
    Raw AS; Furness MS; Gill DS; Adams RC; Holcombe FO; Yu LX
    Adv Drug Deliv Rev; 2004 Feb; 56(3):397-414. PubMed ID: 14962589
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.